Excision locks in $60m

Excision BioTherapeutics, a developer of potentially curative CRISPR anti-viral therapies to improve patient lives, has closed $60 million financing.

Excision BioTherapeutics, a developer of potentially curative CRISPR anti-viral therapies to improve patient lives, has closed $60 million financing. GreatPoint Ventures led the round.

Source: Press Release